Related Experiment Video
Updated: May 5, 2026
13:04
In Vivo and Ex Vivo Approaches to Study Ovarian Cancer Metastatic Colonization of Milky Spot Structures in Peritoneal Adipose
Published on: October 14, 2015
12.8K
Hormone therapy in oophorectomized BRCA1/2 mutation carriers
Claudia Marchetti1, Roberta Iadarola, Innocenza Palaia
1From the Department of Gynecological and Obstetrical Sciences and Urological Sciences, Sapienza University of Rome, Rome, Italy.
Menopause (New York, N.Y.)
|November 21, 2013
Summary
Hormone therapy (HT) may improve quality of life for BRCA1/2 mutation carriers after prophylactic salpingo-oophorectomy. Short-term HT appears safe for cancer outcomes in women without a personal history of breast cancer.
Area of Science:
- Oncology
- Genetics
- Gynecology
Background:
- BRCA1/2 mutations significantly increase risks for breast, ovarian, and fallopian tube cancers.
- Bilateral prophylactic salpingo-oophorectomy is recommended for cancer prevention in these high-risk women.
- This surgery often induces premature menopause, leading to symptoms and potential health risks.
Purpose of the Study:
- To review indications, timing, and implications of salpingo-oophorectomy in BRCA-positive women.
- To focus on the risks and benefits of hormone therapy (HT) post-surgery.
- To evaluate existing trials on HT in BRCA mutation carriers.
Main Methods:
- Review of literature on salpingo-oophorectomy and HT in BRCA mutation carriers.
- Analysis of retrospective and prospective trials.
- Focus on oncologic outcomes and quality of life.
Main Results:
- Surgical menopause causes symptoms impacting quality of life.
- HT can alleviate vasomotor symptoms and improve sexual function.
- Current data suggest HT does not negatively affect survival.
Conclusions:
- Short-term HT may enhance quality of life for BRCA1/2 carriers post-surgery.
- HT does not appear to adversely affect cancer outcomes in selected patients.
- Larger, randomized trials are needed to confirm these findings.
Related Concept Videos
01:30Hormonal Control of the Ovarian Cycle
5.2K
The ovarian cycle is meticulously regulated by the hypothalamic-pituitary-gonadal axis. This cycle orchestrates the release of a mature oocyte, essential for reproduction.
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle. At puberty, GnRH secretion increases in both frequency and...
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle. At puberty, GnRH secretion increases in both frequency and...
5.2K
02:57Targeted Cancer Therapies
7.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.1K
02:57Targeted Cancer Therapies
1.5K
1.5K
02:07Oogenesis
58.5K
In human women, oogenesis produces one mature egg cell or ovum for every precursor cell that enters meiosis. This process differs in two unique ways from the equivalent procedure of spermatogenesis in males. First, meiotic divisions during oogenesis are asymmetric, meaning that a large oocyte (containing most of the cytoplasm) and minor polar body are produced as a result of meiosis I, and again following meiosis II. Since only oocytes will go on to form embryos if fertilized, this unequal...
58.5K
01:22Hormonal Regulation of the Menstrual Cycle
2.4K
The ovarian cycle regulates endometrial changes throughout a single menstrual cycle via the coordinated action of gonadotrophin-releasing hormone (GnRH) and gonadotrophins.
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH...
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH...
2.4K
01:33Hormonal Regulation
30.5K
The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
30.5K